Analysts Expect CytRx (CYTR) to Post -$0.25 EPS

Equities analysts forecast that CytRx (NASDAQ:CYTR) will announce earnings of ($0.25) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for CytRx’s earnings. CytRx reported earnings of ($0.42) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 40.5%. The firm is expected to report its next quarterly earnings report on Thursday, August 2nd.

On average, analysts expect that CytRx will report full-year earnings of ($0.96) per share for the current financial year. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.80) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for CytRx.

CytRx (NASDAQ:CYTR) last issued its quarterly earnings results on Friday, May 11th. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.09.

A number of analysts have recently commented on the company. HC Wainwright assumed coverage on CytRx in a research report on Thursday, May 3rd. They issued a “buy” rating and a $4.00 price target on the stock. ValuEngine raised CytRx from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.

Shares of CYTR traded up $0.02 during mid-day trading on Friday, reaching $1.35. The company had a trading volume of 4,434 shares, compared to its average volume of 378,359. CytRx has a 52 week low of $1.33 and a 52 week high of $1.34. The stock has a market cap of $37.01 million, a P/E ratio of -0.89 and a beta of 2.04.

CytRx Company Profile

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company's product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS); and in Phase Ib/II trial in combination with ifosfamide in patients with STS.

Get a free copy of the Zacks research report on CytRx (CYTR)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for CytRx (NASDAQ:CYTR)

Receive News & Ratings for CytRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx and related companies with's FREE daily email newsletter.

Leave a Reply